Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anaptysbio (ANAB) Return on Equity (2017 - 2025)

Anaptysbio (ANAB) has disclosed Return on Equity for 9 consecutive years, with 3.4% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity fell 152.0% year-over-year to 3.4%, compared with a TTM value of 3.4% through Dec 2025, down 152.0%, and an annual FY2025 reading of 0.24%, up 158.0% over the prior year.
  • Return on Equity was 3.4% for Q4 2025 at Anaptysbio, down from 2.28% in the prior quarter.
  • Across five years, Return on Equity topped out at 24.76% in Q2 2025 and bottomed at 5.9% in Q2 2024.
  • Average Return on Equity over 5 years is 0.1%, with a median of 0.46% recorded in 2022.
  • The sharpest move saw Return on Equity plummeted -516bps in 2024, then skyrocketed 3066bps in 2025.
  • Year by year, Return on Equity stood at 0.15% in 2021, then plummeted by -162bps to 0.4% in 2022, then crashed by -273bps to 1.49% in 2023, then fell by -26bps to 1.87% in 2024, then crashed by -81bps to 3.4% in 2025.
  • Business Quant data shows Return on Equity for ANAB at 3.4% in Q4 2025, 2.28% in Q3 2025, and 24.76% in Q2 2025.